Jiangsu CoWin Biotech Valuation

Is 688426 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688426 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 688426's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 688426's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688426?

Key metric: As 688426 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688426. This is calculated by dividing 688426's market cap by their current revenue.
What is 688426's PS Ratio?
PS Ratio	20x
Sales	CN¥118.17m
Market Cap	CN¥2.37b

688426 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	14.9x
Enterprise Value/EBITDA	-9.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688426's PS Ratio compare to its peers?

The above table shows the PS ratio for 688426 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	9.8x
688137 Novoprotein Scientific	18.4x	n/a	CN¥2.5b
300381 Guangdong VTR Bio-Tech	4.6x	n/a	CN¥3.7b
300485 Beijing Science Sun Pharmaceutical	9.6x	n/a	CN¥3.9b
688767 Hangzhou Biotest BiotechLtd	6.4x	n/a	CN¥3.3b
688426 Jiangsu CoWin Biotech	20x	n/a	CN¥2.4b

Price-To-Sales vs Peers: 688426 is expensive based on its Price-To-Sales Ratio (20x) compared to the peer average (9.8x).

Price to Sales Ratio vs Industry

How does 688426's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	0.9x	n/a	US$231.90m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688426 is expensive based on its Price-To-Sales Ratio (20x) compared to the CN Biotechs industry average (7.6x).

Price to Sales Ratio vs Fair Ratio

What is 688426's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688426 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	20x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 688426's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hunan Jiudian Pharmaceutical

CN¥12.2b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥24.71

-0.2%

5.1%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.87

-5.5%

11.1%